$TEVA · TEVA PHARMACEUTICAL INDUSTRIES LTD SEC Filings
Position Tracker tracks 2 SEC EDGAR filings for TEVA PHARMACEUTICAL INDUSTRIES LTD ($TEVA) from November 3, 2026 through November 4, 2026, including 0 Form 10-K annual reports, 1 Form 10-Q quarterly earnings reports, 1 Form 8-K current event disclosures, and 0 Form 4 insider equity transactions. Select any filing below to read the full AI summary, key financial takeaways, and original SEC.gov document.
$TEVA 10-Q — TEVA PHARMACEUTICAL INDUSTRIES LTD
Teva's Pivot to Growth strategy is showing a stark divergence: AUSTEDO is booming (+32% nine-month) while U.S. generics are in freefall (-39% Q3), and surging financial expenses…
$TEVA 8-K — TEVA PHARMACEUTICAL INDUSTRIES LTD
Teva's portfolio transformation is accelerating: innovative brands grew 33% and now drive margin expansion to decade highs, while the WELTRUZA launch and BXCL-501 acquisition bu…